title: Pharmacokinetics of cefotetan in patients with end-stage renal failure on maintenance dialysis.
abstract: The pharmacokinetics of a single intravenous dose of cefotetan were studied in 17 volunteer patients with end-stage renal failure, requiring intermittent haemodialysis in 12 cases or undergoing continuous ambulatory peritoneal dialysis in 5 cases. Between haemodialysis the mean plasma elimination half life was 20.4 h (S.E.M. +/- 2.1). This decreased to 7.5 h (S.E.M. +/- 0.6) during haemodialysis. In patients treated by continuous ambulatory peritoneal dialysis the mean plasma elimination half life was 15.5 h (S.E.M. +/- 1.9). Small amounts of cefotetan (5-9% of the administered dose) were recovered in the peritoneal dialysates removed over the 24 h following the dose.
authors.forename: M J
authors.initials: MJ
authors.lastname: Browning
authors.forename: H A
authors.initials: HA
authors.lastname: Holt
authors.forename: L O
authors.initials: LO
authors.lastname: White
authors.forename: S T
authors.initials: ST
authors.lastname: Chapman
authors.forename: R A
authors.initials: RA
authors.lastname: Banks
authors.forename: D S
authors.initials: DS
authors.lastname: Reeves
authors.forename: R A
authors.initials: RA
authors.lastname: Yates
mesh_terms: D015313:Cefotetan; D002513:Cephamycins / Q000097:blood / Q000378:metabolism*; D005260:Female; D006207:Half-Life; D006801:Humans; D007676:Kidney Failure, Chronic / Q000378:metabolism*; D007700:Kinetics; D008297:Male; D010531:Peritoneal Dialysis, Continuous Ambulatory; D006435:Renal Dialysis
chemical_list: D002513:Cephamycins; D015313:Cefotetan